Nifty
:
24971.90
Sensex
:
81896.79
-140.50 (-0.56%)
-511.38 (-0.62%)
Nifty
Sensex
:
:
24971.90
81896.79
-140.50 (-0.56%)
-511.38 (-0.62%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 500087 | NSE: CIPLA

NSE BSE
1499.10
23-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1499.7
  •  1504.9
  •  1482.1
  •  1499.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  657381
  •  983717579.9
  •  1702.05
  •  1335

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,21,022.90
  • 22.95
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,20,315.16
  • 1.07%
  • 3.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.20%
  • 0.56%
  • 14.13%
  • FII
  • DII
  • Others
  • 26.28%
  • 26.56%
  • 3.27%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.32
  • 7.53
  • 6.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.14
  • 10.90
  • 7.39

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.46
  • 16.97
  • 23.59

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.57
  • 30.29
  • 29.57

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.64
  • 3.97
  • 4.05

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.69
  • 16.33
  • 16.36

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
51.05
65.29
62.33
65.03
P/E Ratio
29.37
22.96
24.05
23.05
Revenue
25447
27145
29540
31843
EBITDA
6291
7128
7241
7537
Net Income
4122
5273
5026
5252
ROA
13.3
15
12.7
11.9
P/B Ratio
4.33
3.88
3.47
3.10
ROE
16.45
18.21
15.16
14.08
FCFF
3192
4081
3766
3827
FCFF Yield
2.87
3.68
3.39
3.45
Net Debt
-5123
-7655
-11068
-13757
BVPS
346.48
386.25
431.94
483.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
6,729.69
6,163.24
9.19%
7,072.97
6,603.81
7.10%
7,051.02
6,678.15
5.58%
6,693.94
6,328.89
5.77%
Expenses
5,192.10
4,847.38
7.11%
5,084.05
4,856.28
4.69%
5,165.43
4,944.40
4.47%
4,978.14
4,834.98
2.96%
EBITDA
1,537.59
1,315.86
16.85%
1,988.92
1,747.53
13.81%
1,885.59
1,733.75
8.76%
1,715.80
1,493.91
14.85%
EBIDTM
22.85%
21.35%
28.12%
26.46%
26.74%
25.96%
25.63%
23.60%
Other Income
289.46
249.33
16.10%
221.61
184.63
20.03%
190.61
176.32
8.10%
160.19
136.29
17.54%
Interest
14.02
17.59
-20.30%
14.64
30.10
-51.36%
15.40
25.80
-40.31%
17.95
16.39
9.52%
Depreciation
308.73
288.34
7.07%
279.80
233.43
19.86%
271.74
290.04
-6.31%
246.68
239.21
3.12%
PBT
1,504.30
1,259.26
19.46%
1,916.09
1,473.81
30.01%
1,789.06
1,594.23
12.22%
1,611.36
1,374.60
17.22%
Tax
279.28
324.86
-14.03%
332.37
405.30
-17.99%
483.04
438.41
10.18%
435.07
378.02
15.09%
PAT
1,225.02
934.40
31.10%
1,583.72
1,068.51
48.22%
1,306.02
1,155.82
13.00%
1,176.29
996.58
18.03%
PATM
18.20%
15.16%
22.39%
16.18%
18.52%
17.31%
17.57%
15.75%
EPS
15.13
11.63
30.09%
19.45
13.08
48.70%
16.13
14.01
15.13%
14.58
12.33
18.25%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
27,547.62
25,774.09
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
Net Sales Growth
-
6.88%
13.28%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
 
Cost Of Goods Sold
-
8,928.99
8,819.57
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
Gross Profit
-
18,618.63
16,954.52
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
GP Margin
-
67.59%
65.78%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
Total Expenditure
-
20,419.72
19,483.04
17,762.83
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
Power & Fuel Cost
-
397.18
364.84
353.61
331.03
308.26
327.43
335.11
298.82
251.73
245.92
% Of Sales
-
1.44%
1.42%
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
Employee Cost
-
4,832.83
4,310.04
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
% Of Sales
-
17.54%
16.72%
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
Manufacturing Exp.
-
1,894.12
1,779.35
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
% Of Sales
-
6.88%
6.90%
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
General & Admin Exp.
-
1,791.63
1,673.94
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
% Of Sales
-
6.50%
6.49%
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
Selling & Distn. Exp.
-
1,834.86
1,724.97
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
% Of Sales
-
6.66%
6.69%
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
Miscellaneous Exp.
-
740.11
810.33
619.43
565.55
508.00
692.12
855.40
968.98
645.54
818.76
% Of Sales
-
2.69%
3.14%
2.72%
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
EBITDA
-
7,127.90
6,291.05
4,990.29
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
EBITDA Margin
-
25.87%
24.41%
21.93%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
Other Income
-
861.87
746.57
512.13
321.73
269.77
369.38
476.57
357.65
228.69
208.21
Interest
-
62.01
89.88
109.54
106.35
160.70
197.36
168.43
114.23
159.38
206.63
Depreciation
-
1,106.95
1,051.02
1,172.11
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
PBT
-
6,820.81
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
Tax
-
1,529.76
1,546.59
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
331.59
Tax Rate
-
22.43%
27.12%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
PAT
-
5,294.37
4,123.14
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
PAT before Minority Interest
-
5,291.05
4,155.31
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
Minority Interest
-
3.32
-32.17
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
PAT Margin
-
19.22%
16.00%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
PAT Growth
-
28.41%
47.02%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
 
EPS
-
65.70
51.16
34.80
31.39
30.00
19.78
19.17
17.54
12.57
17.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
31,193.45
26,706.43
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
Share Capital
161.52
161.47
161.43
161.36
161.29
161.25
161.14
161.02
160.90
160.68
Total Reserves
30,917.81
26,458.42
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
Non-Current Liabilities
-31.04
81.92
183.53
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
Secured Loans
11.98
0.00
332.46
376.20
355.32
304.74
47.70
0.00
0.00
207.00
Unsecured Loans
0.00
0.00
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
Long Term Provisions
148.69
129.26
102.16
100.22
116.17
133.27
121.41
137.92
140.52
144.68
Current Liabilities
5,483.96
5,245.77
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
Trade Payables
2,837.49
2,473.98
2,534.52
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
Other Current Liabilities
772.99
890.98
1,007.60
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
Short Term Borrowings
80.12
247.02
187.90
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
Short Term Provisions
1,793.36
1,633.79
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
Total Liabilities
36,742.17
32,130.02
28,930.34
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
Net Block
9,895.14
9,493.61
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
Gross Block
19,655.92
18,160.54
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
Accumulated Depreciation
9,707.76
8,573.36
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
Non Current Assets
13,453.65
12,688.61
11,731.79
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
Capital Work in Progress
1,566.27
1,152.72
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
Non Current Investment
639.54
642.21
572.52
355.63
545.43
578.80
490.20
157.66
137.36
176.35
Long Term Loans & Adv.
1,038.36
844.39
845.11
736.39
645.57
677.08
455.57
514.96
543.67
426.18
Other Non Current Assets
203.09
442.07
60.38
383.22
102.51
77.61
166.82
255.71
210.06
176.54
Current Assets
23,248.97
19,392.45
16,805.06
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
Current Investments
7,293.23
4,807.01
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
Inventories
5,642.11
5,237.95
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
Sundry Debtors
5,506.37
4,770.66
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
Cash & Bank
799.84
874.97
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
Other Current Assets
4,007.42
567.64
373.99
305.56
1,378.57
1,416.84
1,566.48
1,599.13
1,226.01
1,223.17
Short Term Loans & Adv.
3,481.42
3,134.22
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
Net Current Assets
17,765.01
14,146.68
11,771.79
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
Total Assets
36,702.62
32,081.06
28,536.85
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
5,004.98
4,133.91
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
PBT
6,820.81
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
Adjustment
517.74
640.77
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
Changes in Working Capital
-665.47
-806.10
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
Cash after chg. in Working capital
6,673.08
5,731.39
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,668.10
-1,597.48
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,691.14
-2,988.03
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
Net Fixed Assets
-626.50
-373.49
-600.42
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
Net Investments
-3,557.23
-1,884.41
-935.67
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
Others
492.59
-730.13
-852.42
-425.89
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
Cash from Financing Activity
-1,292.79
-1,200.43
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
Net Cash Inflow / Outflow
21.05
-54.55
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
Opening Cash & Equivalents
512.34
561.33
658.11
790.43
649.13
508.36
853.47
610.35
858.15
545.84
Closing Cash & Equivalent
542.65
512.34
561.33
658.11
790.43
742.38
508.36
853.46
610.35
858.15

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
384.84
329.72
289.24
257.78
226.73
194.85
185.62
175.92
155.15
142.23
ROA
15.36%
13.59%
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
ROE
18.34%
16.63%
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
ROCE
23.64%
22.77%
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
Fixed Asset Turnover
1.96
2.00
1.81
1.82
1.85
1.89
1.79
1.25
1.36
1.40
Receivable days
50.64
45.49
44.13
42.19
47.44
54.10
55.36
68.17
61.60
57.62
Inventory Days
53.61
53.56
61.98
61.53
58.49
56.12
61.13
90.71
91.41
100.43
Payable days
108.56
103.64
111.52
98.28
107.95
128.84
59.02
57.37
46.96
51.51
Cash Conversion Cycle
-4.31
-4.58
-5.41
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
Total Debt/Equity
0.00
0.01
0.02
0.04
0.10
0.18
0.29
0.29
0.33
0.46
Interest Cover
111.00
64.44
37.87
33.85
21.47
12.04
13.34
15.61
8.67
9.36

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • USFDA concludes cGMP inspection at Cipla’s Bengaluru manufacturing facility
    31st May 2025, 10:40 AM

    On conclusion of the inspection, the company received one observation in Form 483

    Read More
  • Cipla’s arm incorporates new wholly owned subsidiary in Germany
    30th May 2025, 16:14 PM

    CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support

    Read More
  • Cipla’s arm acquires 26% stake in AMPIN Energy C&I Eighteen
    30th May 2025, 14:20 PM

    Earlier, Jay Precision Pharmaceuticals had entered into Share Purchase, Subscription and Shareholder’s Agreement

    Read More
  • Cipla’s arm inks pact to acquire 26% stake in AMPIN Energy C&I Eighteen
    20th May 2025, 12:21 PM

    The total consideration to be paid for the said acquisition is up to Rs 1.46 crore

    Read More
  • Cipla’s arm’s Mahape facility classified as VAI by USFDA
    19th May 2025, 10:30 AM

    USFDA had conducted the inspection at said facility from February 18 to February 20, 2025

    Read More
  • Cipla reports 31% rise in Q4 consolidated net profit
    13th May 2025, 17:02 PM

    The total consolidated income of the company increased by 9.46% at Rs 7019.15 crore for Q4FY25

    Read More
  • Cipla’s arm’s Goa facility classified as VAI by USFDA
    21st Apr 2025, 10:10 AM

    USFDA had conducted the inspection at said facility from January 14 to January 20, 2025

    Read More
  • Cipla gets USFDA’s final approval for generic cancer drug
    11th Apr 2025, 09:23 AM

    The product is expected to be launched in H1 FY 2025-26 in the United States of America

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.